{"log_id": 8287854405637133200, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0, "average": 0.999943, "min": 0.999943}, "location": {"width": 25, "top": 124, "height": 24, "left": 1164}, "words": "管"}, {"probability": {"variance": 0, "average": 0.996278, "min": 0.996278}, "location": {"width": 36, "top": 155, "height": 27, "left": 1159}, "words": "文"}, {"probability": {"variance": 0, "average": 0.999451, "min": 0.998349}, "location": {"width": 266, "top": 254, "height": 29, "left": 286}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 4.5e-05, "average": 0.99619, "min": 0.966959}, "location": {"width": 688, "top": 291, "height": 31, "left": 280}, "words": "尚未在对照临床试验中验证人妊娠期间使用20%人血白蛋白的安全性"}, {"probability": {"variance": 6.5e-05, "average": 0.996909, "min": 0.965984}, "location": {"width": 572, "top": 329, "height": 29, "left": 279}, "words": "没有在临床对照试验中观察人血白蛋白对生殖能力的影响"}, {"probability": {"variance": 0, "average": 0.999669, "min": 0.998609}, "location": {"width": 750, "top": 368, "height": 28, "left": 280}, "words": "没有使用20%人血白蛋白进行动物生殖研究。动物试验研究不足以评价生"}, {"probability": {"variance": 1.2e-05, "average": 0.997894, "min": 0.981666}, "location": {"width": 778, "top": 405, "height": 29, "left": 239}, "words": "殖、胚胎或胎儿的发育、妊娠过程和围产期及产后发育期间使用药物的安全性"}, {"probability": {"variance": 3e-06, "average": 0.998565, "min": 0.9931}, "location": {"width": 410, "top": 442, "height": 27, "left": 280}, "words": "但是,人血白蛋白是人血的正常组成成份"}, {"probability": {"variance": 3e-06, "average": 0.998209, "min": 0.994561}, "location": {"width": 126, "top": 516, "height": 29, "left": 289}, "words": "【儿童用药】"}, {"probability": {"variance": 2e-06, "average": 0.997788, "min": 0.995655}, "location": {"width": 142, "top": 553, "height": 29, "left": 280}, "words": "参见用法用量"}, {"probability": {"variance": 1e-06, "average": 0.998988, "min": 0.997973}, "location": {"width": 127, "top": 626, "height": 27, "left": 288}, "words": "【老年用药】"}, {"probability": {"variance": 1e-05, "average": 0.994338, "min": 0.990571}, "location": {"width": 142, "top": 665, "height": 28, "left": 280}, "words": "参见用法用量"}, {"probability": {"variance": 4e-06, "average": 0.998344, "min": 0.994235}, "location": {"width": 173, "top": 739, "height": 28, "left": 289}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.000648, "average": 0.994205, "min": 0.850836}, "location": {"width": 749, "top": 777, "height": 29, "left": 282}, "words": "人血白蛋白不可与其它药物、全血以及浓缩红细胞混合,白蛋白溶液也不得"}, {"probability": {"variance": 0.000111, "average": 0.996168, "min": 0.954042}, "location": {"width": 781, "top": 813, "height": 29, "left": 240}, "words": "与蛋白质水解产物(如肠外营养剂)或含有乙醇的溶液混合以防止蛋白产生沉淀"}, {"probability": {"variance": 3e-06, "average": 0.998509, "min": 0.994521}, "location": {"width": 126, "top": 887, "height": 28, "left": 290}, "words": "【药物过量】"}, {"probability": {"variance": 0.00067, "average": 0.991, "min": 0.89702}, "location": {"width": 663, "top": 922, "height": 46, "left": 279}, "words": "如输注剂量过大或速度过快时,可发生血容量增高的情况。"}, {"probability": {"variance": 9e-06, "average": 0.998587, "min": 0.988402}, "location": {"width": 752, "top": 962, "height": 28, "left": 283}, "words": "心血管负荷过重时首先出现的临床症状(头痛、呼吸困难、颈静脉充盈)或"}, {"probability": {"variance": 6.4e-05, "average": 0.997568, "min": 0.952003}, "location": {"width": 790, "top": 999, "height": 30, "left": 243}, "words": "血压升高,中心静脉压升高和肺水肿时,应立即停止输液,并严密监测患者的血"}, {"probability": {"variance": 2e-06, "average": 0.998273, "min": 0.995715}, "location": {"width": 139, "top": 1038, "height": 28, "left": 242}, "words": "液动力学参数"}, {"probability": {"variance": 1e-06, "average": 0.999483, "min": 0.997784}, "location": {"width": 125, "top": 1111, "height": 26, "left": 290}, "words": "【药理毒理】"}, {"probability": {"variance": 8.5e-05, "average": 0.997388, "min": 0.952405}, "location": {"width": 573, "top": 1147, "height": 29, "left": 282}, "words": "人血白蛋白作为人血浆的正常组成成份,行使其生理功能"}, {"probability": {"variance": 5e-06, "average": 0.998549, "min": 0.991655}, "location": {"width": 745, "top": 1184, "height": 30, "left": 282}, "words": "动物单剂量毒性试验的实用性不大,因其不能评估毒性或致死剂量或剂量"}, {"probability": {"variance": 2.2e-05, "average": 0.998095, "min": 0.972574}, "location": {"width": 793, "top": 1224, "height": 29, "left": 242}, "words": "效应关系。由于动物模型中的异源蛋白可产生抗体,也不可进行重复剂量毒性试"}, {"probability": {"variance": 0, "average": 0.998799, "min": 0.998799}, "location": {"width": 26, "top": 1265, "height": 25, "left": 242}, "words": "验"}, {"probability": {"variance": 0.006761, "average": 0.984298, "min": 0.512104}, "location": {"width": 753, "top": 1297, "height": 29, "left": 282}, "words": "迄今为止,未发现人血白蛋白与胚胎-胎儿毒性、致癌性或潜在有关联的致畸"}, {"probability": {"variance": 0, "average": 0.999869, "min": 0.999867}, "location": {"width": 49, "top": 1337, "height": 27, "left": 243}, "words": "报告"}, {"probability": {"variance": 6e-06, "average": 0.998999, "min": 0.988944}, "location": {"width": 392, "top": 1373, "height": 27, "left": 296}, "words": "动物模型中未发生急性毒性症状的描述"}, {"probability": {"variance": 0, "average": 0.999221, "min": 0.998264}, "location": {"width": 151, "top": 1445, "height": 30, "left": 303}, "words": "【药代动力学】"}, {"probability": {"variance": 0.004917, "average": 0.981429, "min": 0.598386}, "location": {"width": 647, "top": 1484, "height": 27, "left": 297}, "words": "药物治疗组:血浆替代物和血浆蛋白成份、ATC代码:BO5AA01"}], "language": 3}